HK1198942A1 - Concentrated felbamate formulations for parenteral administration - Google Patents

Concentrated felbamate formulations for parenteral administration

Info

Publication number
HK1198942A1
HK1198942A1 HK14112610.9A HK14112610A HK1198942A1 HK 1198942 A1 HK1198942 A1 HK 1198942A1 HK 14112610 A HK14112610 A HK 14112610A HK 1198942 A1 HK1198942 A1 HK 1198942A1
Authority
HK
Hong Kong
Prior art keywords
felbamate
formulations
concentrated
parenteral administration
parenteral
Prior art date
Application number
HK14112610.9A
Other languages
English (en)
Chinese (zh)
Inventor
Sasha H Bakhru
Bryan E Laulicht
Edith Mathiowitz
Solomon S Steiner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198942A1 publication Critical patent/HK1198942A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HK14112610.9A 2011-08-12 2014-12-16 Concentrated felbamate formulations for parenteral administration HK1198942A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161522811P 2011-08-12 2011-08-12
PCT/US2012/050148 WO2013025442A2 (en) 2011-08-12 2012-08-09 Concentrated felbamate formulations for parenteral administration

Publications (1)

Publication Number Publication Date
HK1198942A1 true HK1198942A1 (en) 2015-06-19

Family

ID=47715640

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112610.9A HK1198942A1 (en) 2011-08-12 2014-12-16 Concentrated felbamate formulations for parenteral administration

Country Status (7)

Country Link
US (2) US20140178479A1 (ja)
EP (1) EP2741751A4 (ja)
JP (3) JP2014525402A (ja)
AU (1) AU2012295390B2 (ja)
CA (1) CA2844907A1 (ja)
HK (1) HK1198942A1 (ja)
WO (1) WO2013025442A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032166T2 (en) 2009-11-02 2017-09-28 Univ Washington Therapeutic nuclease preparations and methods
KR102428875B1 (ko) 2011-04-29 2022-08-05 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
US10988745B2 (en) 2013-10-31 2021-04-27 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
WO2015100252A1 (en) * 2013-12-23 2015-07-02 Perosphere, Inc. Deuterated felbamate, compositions containing the same, and methods of use thereof
GB201604359D0 (en) * 2016-03-15 2016-04-27 Univ Newcastle Treatment of tissue disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1904257A (en) * 1926-10-29 1933-04-18 Firm Of Chemical Works Formerl Supersaturated calcium gluconate solution
US3017323A (en) * 1957-07-02 1962-01-16 Pfizer & Co C Therapeutic compositions comprising polyhydric alcohol solutions of tetracycline-type antibiotics
US5308621A (en) * 1991-02-18 1994-05-03 Commonwealth Scientific And Industrial Research Organisation Ascorbic acid composition and transdermal administration method
US6020367A (en) * 1997-12-02 2000-02-01 Avon Products, Inc. Supersaturated ascorbic acid solutions
MXPA01007968A (es) * 1999-02-09 2003-07-14 Univ Virginia Compuestos derivados del felbamato.
JP4763957B2 (ja) 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
JP2006516642A (ja) * 2003-02-03 2006-07-06 シャイア ラボラトリーズ，インコーポレイテッド 薬物製剤およびメチル化シクロデキストリン結晶を用いた送達
EP1628641A2 (en) * 2003-05-19 2006-03-01 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
WO2004105699A2 (en) 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
EP1928464B1 (en) * 2005-09-30 2014-05-14 Lundbeck Inc. Novel parenteral carbamazepine formulation
US20090209480A1 (en) * 2006-01-17 2009-08-20 The Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for cns conditions
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
WO2009017825A2 (en) 2007-08-02 2009-02-05 The General Hospital Corporation Novel lipoxygenase inhibitors as neuroprotective agents
AU2009257994A1 (en) * 2008-04-01 2009-12-17 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for the intracerebroventricular administration of felbamate
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
PL3238709T3 (pl) * 2011-04-28 2021-02-08 Platform Brightworks Two, Ltd. Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania

Also Published As

Publication number Publication date
AU2012295390B2 (en) 2015-12-24
AU2012295390A1 (en) 2014-03-13
WO2013025442A3 (en) 2013-04-25
WO2013025442A2 (en) 2013-02-21
JP2014525402A (ja) 2014-09-29
EP2741751A2 (en) 2014-06-18
JP2017122127A (ja) 2017-07-13
US20140178479A1 (en) 2014-06-26
CA2844907A1 (en) 2013-02-21
EP2741751A4 (en) 2015-03-25
US20170157083A1 (en) 2017-06-08
JP2019085416A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
ZA201401012B (en) Parenteral novovirus vaccine formulations
ZA201309245B (en) Novel fluoroergoline analogs
PT2672973T (pt) Regime de administração para nitrocatecóis
HRP20160989T1 (hr) Otopina za oralnu primjenu
HK1194964A1 (zh) 他噴他多的腸胃外給藥
HK1198942A1 (en) Concentrated felbamate formulations for parenteral administration
EP2667750A4 (en) DISPLAY OF MERCHANDISE
EP2687212A4 (en) DRUG AGENT
GB201110278D0 (en) Formulations
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
PL394696A1 (pl) Pochodna leku przeciwwirusowego
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201104049D0 (en) Formulations
GB201102795D0 (en) Formulations